ERBB2 emerges as a new target for colorectal cancer.

Abstract excerpt

ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Neoplasms
• Share to EGFR gene
• Share to ERBB2 gene